Edition:
United Kingdom

ProQR Therapeutics NV (PRQR.OQ)

PRQR.OQ on NASDAQ Stock Exchange Global Market

11.21USD
25 Apr 2019
Change (% chg)

$-0.26 (-2.27%)
Prev Close
$11.47
Open
$11.53
Day's High
$11.55
Day's Low
$11.01
Volume
52,494
Avg. Vol
85,412
52-wk High
$24.00
52-wk Low
$3.50

Latest Key Developments (Source: Significant Developments)

ProQR Spins Out All Dystrophic Epidermolysis Bullosa Activities
Tuesday, 26 Mar 2019 

March 26 (Reuters) - ProQR Therapeutics NV ::PROQR SPINS OUT ALL DYSTROPHIC EPIDERMOLYSIS BULLOSA ACTIVITIES INTO NEWLY FORMED WINGS THERAPEUTICS CREATED BY EB RESEARCH PARTNERSHIP.PROQR THERAPEUTICS NV - WINGS THERAPEUTICS IS FORMED AND FINANCED BY EB RESEARCH PARTNERSHIP.PROQR THERAPEUTICS NV - FINANCIAL DETAILS WERE NOT DISCLOSED.PROQR THERAPEUTICS NV - WINGS THERAPEUTICS WILL BE LED BY INTERIM CEO MARK DE SOUZA.PROQR THERAPEUTICS NV - PROQR HAS A MINORITY STAKE IN WINGS THERAPEUTICS AND WILL BE ELIGIBLE FOR MILESTONE AND ROYALTY RIGHTS TO COMMERCIAL PRODUCTS.PROQR - SUBSEQUENT TO PLANNED INTERIM ANALYSIS AND STRATEGIC REVIEW, ELECTED TO TRANSFER COMPLETION OF ONGOING PHASE 1/2 STUDY TO WINGS THERAPEUTIC.PROQR THERAPEUTICS NV - HAL LANDY TO ALSO LEAD WINGS THERAPEUTICS WITH MARK DE SOUZA.PROQR THERAPEUTICS NV - ONGOING PHASE 1/2 TRIAL IN PATIENTS WITH DEB DUE TO A MUTATION IN EXON 73 WILL REMAIN BLINDED AND CONTINUES TO ENROLL PATIENTS.PROQR THERAPEUTICS NV - WINGS THERAPEUTICS WILL FOCUS ON DEVELOPING THERAPIES FOR DYSTROPHIC EPIDERMOLYSIS BULLOSA.  Full Article

Proqr Therapeutics NV Reports Q4 Loss Per Share Of EUR 0.33
Wednesday, 27 Feb 2019 

Feb 27 (Reuters) - ProQR Therapeutics NV ::PROQR REPORTS FOURTH QUARTER AND FULL YEAR 2018 OPERATING AND FINANCIAL RESULTS.Q4 LOSS PER SHARE EUR 0.33.  Full Article

Proqr Therapeutics NV Files For Mixed Shelf Of Up To $300 Mln
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - ProQR Therapeutics NV ::PROQR THERAPEUTICS NV FILES FOR MIXED SHELF OF UP TO $300 MILLION – SEC FILING.  Full Article

Adage Capital Reports 5.88 Pct Passive Stake In ProQR Therapeutics
Friday, 25 May 2018 

May 25 (Reuters) - ProQR Therapeutics NV ::ADAGE CAPITAL PARTNERS REPORTS 5.88 PERCENT PASSIVE STAKE IN PROQR THERAPEUTICS NV AS OF MAY 17 - SEC FILING.  Full Article

Proqr Q4 Loss Per Share ‍Eur 0.39
Wednesday, 28 Feb 2018 

Feb 28 (Reuters) - Proqr Therapeutics Nv ::PROQR ANNOUNCES RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2017 AND PROVIDES BUSINESS UPDATE.PROQR THERAPEUTICS NV - ‍CASH OF EUR 48.0 MILLION AT YEAR-END EXPECTED TO FUND OPERATIONS THROUGH ANTICIPATED CLINICAL DATA READOUTS IN 3 DIFFERENT PROGRAMS​.PROQR THERAPEUTICS NV QTRLY LOSS PER SHARE ‍ EUR 0.39.  Full Article

ProQR And Galapagos Announce Research Collaboration
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Galapagos Nv ::PROQR AND GALAPAGOS ANNOUNCE RESEARCH COLLABORATION ON FIBROSIS TARGETS USING PROQR’S AXIOMER® TECHNOLOGY.PROQR THERAPEUTICS - UNDER AGREEMENT, TWO COMPANIES WILL WORK TOGETHER TO DISCOVER NOVEL AXIOMER EONS AGAINST FIBROSIS TARGETS SELECTED BY GALAPAGOS.PROQR THERAPEUTICS NV- TARGETS THAT WILL BE PURSUED IN COLLABORATION AND FINANCIAL DETAILS ABOUT COLLABORATION ARE NOT DISCLOSED.  Full Article

Proqr reports loss of EUR 0.42 per share​
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Proqr Therapeutics Nv :Proqr announces results for the third quarter of 2017.Proqr Therapeutics Nv - ‍net result for three month period ended September 30, 2017 was a EUR 10.5 million loss or EUR 0.42 per share​.  Full Article

ProQR Therapeutics prices public offering
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - ProQR Therapeutics Nv :ProQR prices approximately $20 million underwritten public offering and concurrent registered direct offering of ordinary shares.Pricing of offering of its ordinary shares at a price to public of $3.25 per share​.  Full Article

Proqr announces proposed public offering of ordinary shares
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Proqr Therapeutics Nv :Proqr announces proposed public offering of ordinary shares.Proqr - To use proceeds from both offerings to fund clinical trials, ongoing research & development activities​.  Full Article

ProQR doses first LCA 10 patient in clinical trial of QR-110
Monday, 13 Nov 2017 

Nov 13 (Reuters) - ProQR Therapeutics NV :ProQR doses first LCA 10 patient in clinical trial of qr-110, ProQR's lead program for genetic blindness.ProQR Therapeutics - ‍interim safety and efficacy trial results for QR-110​ from majority of patients after 6 months of treatment are expected in 2018.ProQR Therapeutics - full 12 month treatment data for QR-110 from all patients are expected in 2019​.  Full Article